Amgen Inc. (AMGN) Holdings Cut by Capstone Asset Management Co.
Capstone Asset Management Co. trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 125,131 shares of the medical research company’s stock after selling 6,252 shares during the period. Amgen accounts for about 0.6% of Capstone Asset Management Co.’s holdings, making the stock its 23rd largest holding. Capstone Asset Management Co.’s holdings in Amgen were worth $21,551,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Jackson Grant Investment Advisers Inc. lifted its holdings in Amgen by 0.6% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the last quarter. Conservest Capital Advisors Inc. lifted its holdings in Amgen by 0.4% during the 2nd quarter. Conservest Capital Advisors Inc. now owns 3,130 shares of the medical research company’s stock worth $539,000 after buying an additional 13 shares during the last quarter. M Holdings Securities Inc. lifted its holdings in Amgen by 0.6% during the 1st quarter. M Holdings Securities Inc. now owns 2,825 shares of the medical research company’s stock worth $463,000 after buying an additional 18 shares during the last quarter. Kovitz Investment Group Partners LLC lifted its holdings in Amgen by 1.2% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 3,223 shares of the medical research company’s stock worth $529,000 after buying an additional 38 shares during the last quarter. Finally, AMG Funds LLC lifted its holdings in Amgen by 0.4% during the 1st quarter. AMG Funds LLC now owns 10,089 shares of the medical research company’s stock worth $1,655,000 after buying an additional 41 shares during the last quarter. 78.09% of the stock is owned by institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.25% during midday trading on Thursday, reaching $187.70. The company’s stock had a trading volume of 753,126 shares. The stock has a 50 day moving average of $175.99 and a 200-day moving average of $169.31. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $191.10. The company has a market capitalization of $136.96 billion, a P/E ratio of 17.10 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same quarter last year, the business earned $2.84 earnings per share. Amgen’s revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts anticipate that Amgen Inc. will post $12.57 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were paid a $1.15 dividend. The ex-dividend date was Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.44%. Amgen’s payout ratio is currently 41.93%.
A number of analysts have issued reports on AMGN shares. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $189.00 price target on shares of Amgen in a report on Friday, June 30th. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Credit Suisse Group set a $177.00 target price on Amgen and gave the stock a “hold” rating in a research report on Friday, July 14th. Morgan Stanley lifted their target price on Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 13th. Finally, Deutsche Bank AG reiterated a “hold” rating and set a $174.00 target price (up previously from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $186.14.
COPYRIGHT VIOLATION WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/21/amgen-inc-amgn-holdings-cut-by-capstone-asset-management-co.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.